85 results about "Bladder cancer patient" patented technology

The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer.

ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip. Gene expression in bladder cancer was validated using reverse transcription-polymerase chain reaction (RT-PCR), quantitative PCR, and in situ hybridization. Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.

The presence and relative amount of ADAM12 in the urine of cancer patients were determined by Western blotting and densitometric measurements, respectively.

Particularly ADAM12 mRNA expression was significantly upregulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage. ADAM12 protein expression correlated with tumor stage and grade. ADAM12 was present in higher levels in the urine from bladder cancer patients than in urine from healthy individuals. Significantly, following removal of tumor by surgery, in most bladder cancer cases examined the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.

The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.

The invention provides an STAG2 gene mutant sequence and a detection method thereof as well as use of STAG2 gene mutation in detecting bladder cancer and belongs to the technical field of the molecular biology gene detection. The detection method comprises the following steps: (1) extracting a tumor tissue DNA and a peripheral blood DNA from a tumor tissue and the peripheral blood of a bladder cancer patient; (2) performing whole genome sequencing and whole exon sequencing on the two DNAs extracted in the step (1), respectively; (3) performing whole exome sequence alignment and somatic mutation detection on the sequencing results of the step (2), thereby obtaining a mutant gene; (4) verifying the somatic replacement, insertion and deletion of the mutant gene obtained in the step (3) by use of Sanger sequencing; and (5) identifying the mutant gene as the remarkable mutant gene. The detection method has the advantage that the mutation of the STAG2 is one of unfavorable indexes of the bladder cancer and also is capable of serving as a new acting target for treating the bladder cancer.

The invention provides a bladder cancer patient urine specific metabolite spectrum, an establishing method and an application, and especially provides a method for establishing a spectrum of specific metabolites in urine of bladder cancer patients, and a method for screening a related specific biomarker. Through metabonomics, especially metabonomics based on liquid chromatography-mass spectrometry combined technology, the invention establishes a bladder cancer patient urine specific metabolite spectrum. The invention provides a basis for early diagnosis of bladder cancer and bladder cancer diseases with different pathological stages, and also provides a spectrum of specific metabolites in urine of bladder cancer patients and a related specific biomarker. The method provided by the invention has the characteristics of noninvasiveness, convenience, and rapidness, can accurately reflect the difference of metabolite spectra of bladder cancer patients and normal people, and has high specificity.

The invention discloses a method for rapidly detecting the bladder cancer with quantum dot labeling immune chromatographic test paper. The existing method for bladder cancer detection comprises the cystoscope, ultrasonic waves, CT, and the like, but the methods are trivial in detection procedures and patients are subjected to pains. By making use of the quantum dot labeling immune chromatographic test paper, the method rapidly detects the amount of fibronectin protein contained in urine of bladder cancer patients and diagnoses and judges the bladder cancer. The detection method which is low in cost and simple in method is suitable for samples of blood, urine, saliva, and the like, can be applied to the detection of hormones, proteins, viruses, drugs, bacteria, environmental pollution, and the like, and can be used in places such as hospitals, customs, , airports and families.

The invention relates to a test paper for quantitative detection of bladder cancer, which is composed of a sample pad, a colloidal gold pad, a nitrocellulose membrane, an absorbent paper and a bottom plate. On the nitrocellulose membrane, there is a detection area fixed with urinary fibronectin and sheep antibody. In the control area of ​​the mouse secondary antibody, there is a gold-labeled anti-urinary fibronectin antibody on the colloidal gold pad, wherein the gold-labeled antibody is dispersed on the colloidal gold pad after being dispersed in a pH 5-10 dilution. The sensitivity of quantitative detection is up to 10ng/mL, the linear range is from 10-3000ng/mL, and it has the advantages of strong specificity, high precision, good stability, easy operation, low cost, etc. It is suitable for primary screening and surgical treatment of bladder cancer. After tracking.

The invention provides an integrated detection method for separating, enriching and detecting an exosome. The method comprises the following steps: designing and assembling a dual-membrane filtration chip, constructing an ELISA detection standard curve, collecting a sample, injecting and washing, performing chip ELISA detection, and performing data processing analysis. The invention also provides an integrated detection chip for separating, enriching and detecting a urine exosome. A reaction system and the detection method of the present invention can be used for detecting the content of a urine sample of a bladder cancer patient and the exosome in a supernatant of a bladder cancer cell line nutrient solution. The detection chip has characteristic of high specificity, generates no influence or wound on human body, and the detection method does not require the expensive precision experiment apparatus (such as an ultra centrifuge and a fluorescence microscope), and has large application prospect.

The invention relates to a serum micro ribonucleic acid (miRNA) biomarker used for detection of bladder cancer, overcomes the defects in the prior art, provides a miRNA marker circulating in serum of a patient having the bladder cancer, establishes a blood circulation miRNA expression profile of the patient having the bladder cancer, discloses the value of serum miRNAs in diagnosis of the bladder cancer, and provides support for early detection and early treatment of the patient having the bladder cancer clinically. According to the serum miRNA biomarker of the bladder cancer and a detection method of expression quantity of the serum miRNA biomarker, for the first time, the serum miRNAs, especially miR-663b and miR-497 can be used as an important indicator of biological detection and plays roles in clinical early diagnosis of the bladder cancer, differential diagnosis and effective observation, a theoretical basis is provided for research on the serum miRNAs of urinary system tumor in the future, novel ideas are provided for the diagnosis of the bladder cancer at the molecular level, and the serum miRNA biomarker of the bladder cancer and the detection method of expression quantity of the serum miRNA biomarker have great theoretical significance and potential practical value.

The invention relates to a urine-based method and kit for diagnosing the relapse risk of a bladder cancer patient. The invention discloses two methylation-sensitive genes, namely an LMX1A gene and a VAX1 gene. A urine sample is kept before the operation of a detected bladder cancer patient, and the specific CpG sites of the genes are subjected to high methylation among people who are determined to suffer from a relapse in the follow-up visit process. Thus, the two genes can be used as biological markers for the relapse of bladder cancer. The invention can be used as the basis for designing a kit for prognosing and diagnosing the relapse of bladder cancer, and is applicable to the prognosis detection of bladder cancer in hospital, the postoperative follow-up visit and the postoperative monitoring of the community health center on people subjected to bladder cancer operation.

The invention provides application of long-chain non-coding RNA DUXAP8 as a biomarker for prognosis of bladder cancer. The application is characterized in that the long-chain non-coding RNA DUXAP8 isused for predicting the overall survival time or recurrence-free survival time of bladder cancer patients. The application successfully provides a high-efficiency biomarker resource for the prognosisof the disease by detecting the change in the frequency of the genomic site copy number of the long-chain non-coding RNA DUXAP8.

The invention discloses a bladder drug flushing and perfusion device after a urinary system surgery. By means of a drug adding mechanism, drug components can be added to perfusate, an affected part can be treated by diminishing inflammation and arresting bleeding in a perfusion process, and even bladder chemotherapy drugs can be perfused for a bladder cancer patient after a surgery; by means of a heating mechanism, the perfusate can be heated, and proper heating can reduce the stress response, improve the use experience of the patient in colder weather, and improve the drug effect; by means of a temperature sensor, the internal temperature of the bladder can be detected to realize temperature control, and when the internal temperature is lower than the lower limit of the preset temperature, liquid circulation is accelerated; and by means of a pressure sensor, the liquid pressure inside the bladder can be detected, so that on one hand, proper filling inside the bladder is ensured, and on the other hand, when the urinary tract is blocked by blood clots or other reasons, early warning can be given to avoid discomfort caused by overfilling of the bladder and improve the use experience of the patient. Therefore, the device disclosed by the invention has certain application prospects.

The invention relates to application of an ATF (activating transcription factor) 3 protein to preparation of a kit for detecting or judging bladder cancer metastasis and judging bladder cancer prognosis. The invention also provides the kit for detecting or judging bladder cancer metastasis and judging bladder cancer prognosis. The invention has the following advantages: the invention provides a new protein marker for predicting bladder cancer metastasis of patients with bladder cancers and judging prognosis and the protein marker can be used for detecting or judging bladder cancer invasion and metastasis degrees and judging prognosis by an immunohistochemical detection method; the invention provides the new kit for predicting bladder cancer metastasis of the patients with bladder cancers and judging prognosis; and the invention provides the new application of the ATF 3 protein to suppressing bladder cancer metastasis and lengthening the prognostic lifetime of the patients with bladder cancers.

The invention provides a maker for predicting bladder cancer chemosensitivity. The marker is a combinationof SOCS1 and CYLD genes. According to the marker for predicting the bladder cancer chemosensitivity and the marker being the combination of the SOCS1 and the CYLD genes, the jointly-predicted area under a ROC curve by the combination of the SOCS1 and the CYLD genes is 0.9641, sensitiveness reaches 92.51%, and specificity reaches 91.31%. According to the marker for predicting the bladder cancer chemosensitivity and application, sensibility of a bladder cancer patient to chemotherapy drug gemcitabine can be quickly and accurately mastered by a clinician, the foundation is laid for the clinic treatment effect, help is provided for discoveringnovel drug targets which have potential treatment values and enhance the sensibility of the chemotherapy drug gemcitabine, and good application values and prospects are achieved.

The invention belongs to the technical field of bioengineering and tumor markers, and relates to a prognosis model for the total survival rate of a bladder cancer patient, in particular to a prognosis model capable of predicting the total survival rate of the bladder cancer patient based on 12 DNA repair related genes. According to the invention, a prognosis model with 12 DRRGs is established, and bladder cancer patients are divided into high-risk and low-risk groups. The risk score of the bladder cancer patient in the training queue is significantly related to the OS (Plt, 0.001, HR = 6.3 [4.1, 9.8]). ROC curve analysis shows that AUC is 0.763 and 0.735 and 0.735 and 0.735 respectively in follow-up visits in one year, three years and five years. The prediction performance has been verified in the test set.

The invention belongs to the technical field of tumor biological gene therapy, and relates to a bladder cancer diagnosis and treatment biomarker and a target spot, in particular to application of circ-SLC38A1 as a target spot in a bladder cancer cell inhibition medicine. The invention discloses an expression condition of circ-SLC38A1 in tumor tissues of a bladder cancer patient and a function of circ-SLC38A1 in bladder cancer cells. It is found for the first time that circ-SLC38A1 can be used as a bladder cancer diagnosis biomarker and a drug therapy target. Compared with normal control, circ-SLC38A1 is significantly up-regulated in tumor tissues of bladder cancer patients. The result of the invention shows that interference on circ-SLC38A1 can inhibit the migration and invasion ability ofbladder cancer cells, and it is shown that the circ-SLC38A1 plays a role of a cancer-promoting gene in the occurrence and development of bladder cancer, and provides a new target for clinical treatment of bladder cancer.

The invention relates to a bladder cancer pathomics intelligent diagnosis method based on machine learning and a prognosis model thereof, and the method is characterized in that the method comprises the following steps: S1, preforming data acquisition; S2, processing a microscopic pathology image; S3, performing bladder cancer pathological image feature extraction; S4, constructing and inspectinga bladder cancer automatic pathological diagnosis model based on machine learning; and S5, constructing and checking a bladder cancer survival prognosis prediction model based on machine learning. Thebladder cancer pathomics intelligent diagnosis method has the advantages that the bladder cancer pathomics intelligent diagnosis method is constructed based on pathological section microscopic imagemachine learning, effective automatic pathological diagnosis can be achieved, pathological diagnosis is expected to be further promoted to be developed to the efficient and accurate field, and the current situation that domestic pathology physicians are in shortage is relieved; the postoperative survival condition of the bladder cancer patient can be efficiently and accurately predicted, and important guidance opinions are provided for clinical decisions of clinicians.

The invention discloses a polymer nano sensor and application of the polymer nano sensor in detection of hyaluronidase type 1 (Hyal-1). Based on the principle that different hyaluronidase differentially degrades hyaluronic polymer nano-micelles, hydrogen bond induced enhanced dye molecules are wrapped in nano-micelle particles, and a high-selectivity and high-sensitivity Hyal-1 fluorescent nano-sensor is designed by utilizing stimulus-responsive nano-materials to adjust the interaction between dye and water molecules. A type I hyaluronidase detection kit comprises a type I hyaluronidase fluorescent nano sensor and a solvent. Results show that the kit has the advantages of high specificity, good sensitivity, simplicity and convenience in operation, economy, practicability and the like; andthe detection of Hyal-1 in an actual urine sample is realized. Therefore, the method provided by the invention has original innovativeness, good social values and application prospects, and is expected to be applied to detection and analysis of Hyal-1 in urine of bladder cancer patients.

The invention refers to a novel molecular biomarker, namely PTPD1, that is markedly increased in human bladder cancers. PTPD1 expression positively correlated with the grading and invasiveness potential of these tumors. PTPD1 can be detected at high levels in exfoliated bladder cells isolated from urine of bladder cancer patients, while no PTPD1 signal was evident in normal exfoliated bladder cells. Thus, PTPD1 detection in urine samples may represent a novel and reliable marker for non-invasive diagnosis of aggressive bladder cancer.

The invention relates to a method for detecting the urine fibronectin, and a kit thereof. The method comprises the steps of specimen acquisition, experiment preparation, sample addition, incubation, plate washing, enzyme addition, incubation, washing, color development and termination. A bladder cancer diagnosis technology having the advantages of simplicity, rapidness, non-invasion, low price, high sensitivity and strong specificity is established in the invention to determine the concentrations of the urine fibronectin of a bladder cancer patient in different pathological phases, and the index of the bladder cancer infiltration degree can be discriminated through the difference of the urine fibronectin.

The invention discloses a bladder cancer depleted NKT cell subset, a characteristic gene and application thereof. The bladder cancer depleted NKT cell subset is characterized in that a single cell transcriptome sequencing analysis technology is utilized to perform single cell transcriptome sequencing on NKT cells from peripheral blood, normal bladder tissues and bladder cancer tissues of an infiltrative bladder cancer patient, a bladder cancer specific NKT cell subset, namely CD8<+> depleted NKT cells, is identified, and characteristic genes expressed by the CD8<+> depleted NKT cells, namely genes CSF2, ATF3, BAG3, NR4A1 and NR4A2, are determined. Moreover, the characteristic genes can be used for identifying or identifying the CD8<+> depleted NKT cells from the bladder cancer, and furtherused for auxiliary diagnosis, prognosis and immunotherapy of the bladder cancer, and provide a related detection reagent or kit.

The invention belongs to the technical field of biological detection, and specifically relates to a rapid detection kit for nuclear matrix protein 22 and application thereof. The rapid detection kit for the nuclear matrix protein 22 disclosed by the invention mainly consists of a solid-phase carrier enveloped by a monoclonal antibody to the nuclear matrix protein 22, the monoclonal antibody to the nuclear matrix protein 22 labelled by horseradish peroxidase, acridinium ester, washing liquid and nuclear matrix protein 22 calibrator. The rapid detection kit for the nuclear matrix protein 22 disclosed by the invention can detect an expression level of the nuclear matrix protein 22 in body fluid of a patient after surgical treatment or recurrent and metastatic tumor patient, and has an important meaning for clinical diagnosis of bladder cancer; and the rapid detection kit for the nuclear matrix protein 22 disclosed by the invention has the advantages of high accuracy and stability in a detection result and good sensitivity, and is favorable for early diagnosis and prognosis treatment of the bladder cancer.